M a i n r e s u l t s 5 RCTs (n = 11 036) (mean age 65 y, 60% men) were included in the intention-to-treat meta-analysis of individual patient data using a logistic regression model with random effects for trial and fixed effects for treatment assignment. Odds ratios (ORs) were adjusted for trial, age, sex, qualifying event, and history of hypertension. Dipyridamole plus aspirin (combination group) vs control (including placebo) (4 RCTs): Risk for recurrent fatal and nonfatal stroke (all stroke) was lower in the combination group than in the control group (Table) 
C o n c l u s i o n
In patients with a history of ischemic cerebrovascular disease, dipyridamole given with or without aspirin reduces the risk for recurrent stroke. 
C o m m e n t a r y
The meta-analysis by Leonardi-Bee and colleagues and that by De Schryver and colleagues (1) suggest that a combination of dipyridamole and aspirin is significantly, but marginally, more effective than aspirin in preventing major vascular events (OR 0.84, CI 0.72 to 0.97). However, the combination remains to be established as first-line treatment for transient ischemic attack (TIA) and stroke because it costs more and may cause more headache, gastrointestinal upset, and angina in patients with occlusive coronary artery disease. It is important to note that the positive result is mainly driven by a single RCT, the European Stroke Prevention Study 2 (ESPS II) (2) , and the size of the effect may be as low as a 3% odds reduction. Completion of the European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) (equivalent to ESPS II in power) (3) will add data and substantially improve the precision of the estimate of the treatment effect for combination therapy. For the time being, aspirin remains the most affordable and widely available antiplatelet therapy for patients with TIA and ischemic stroke (relative risk reduction for recurrence 13%, CI 6 to 19) (4).
